Brief: Standard BioTools Enters Strategic Sale Of SomaLogic To Illumina
23/06/2025 12:11
June 23 (Reuters) - STANDARD BIOTOOLS- DEAL VALUED AT UP TO $425 MILLION WITH $350 MILLION UPFRONT STANDARD BIOTOOLS ENTERS NEXT PHASE OF TRANSFORMATION WITH STRATEGIC SALE OF SOMALOGIC TO ILLUMINA Source text: ID:nGNX14Dxx Further company coverage: ILMN.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Illumina
See all newsBrief: Illumina Bioinsight Platform Expands With New Software To Accelerate The Path From Sequencing To Discovery
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Illumina - Establishes Unsecured Commercial Paper Program On October 8, 2026
Brief: Illumina To Announce Third Quarter 2026 Financial Results
Brief: Illumina Releases Spliceai2 To Help Advance Rare Disease Research